Engineered immune cells take on rare sarcomas in early trial
NCT ID NCT07467122
First seen Mar 20, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This early-phase trial is testing a new treatment for people with advanced mesenchymal malignancies (a group of rare cancers including sarcomas). The treatment uses the patient's own immune T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called MAGE-A4. The study will enroll 15 participants to primarily check safety and see if the tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MESENCHYMAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TCR-T cells targeting MAGE-A4
What this could lead to
If it works, this could point toward a new treatment option for advanced mesenchymal cancers that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 15 participants, so it is too small to prove effectiveness. There are also risks of serious side effects like cytokine release syndrome or neurotoxicity.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.